US2013261097A1PendingUtilityA1
Pharmaceutical composition and method for treating hypogonadism
Est. expiryAug 30, 2020(expired)· nominal 20-yr term from priority
A61P 5/00A61P 5/26A61P 15/08A61K 9/06A61K 47/14A61K 31/565A61K 47/12A61K 9/0014A61K 31/5685A61K 31/568A61K 47/10A61K 47/32
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.
Claims
exact text as granted — not AI-modified1 .- 73 . (canceled)
74 . A gel pharmaceutical composition comprising:
a) about 0.1% to about 10.0% (w/w) testosterone; b) about 30.0% to about 98.0% (w/w) ethanol; c) about 0.1% to about 5.0% (w/w) isopropyl myristate; d) about 0.1% to about 5.0% (w/w) of an anionic polymer neutralized with an amount of sodium hydroxide; and e) water.
75 . The pharmaceutical composition of claim 74 , wherein the anionic polymer is a polyacrylic acid.
76 . The gel pharmaceutical composition of claim 75 , wherein the polyacrylic acid is a carbopol.
77 . The gel pharmaceutical composition of claim 74 , wherein the sodium hydroxide is 0.1 N NaOH and the anionic polymer is a carbopol.
78 . The gel pharmaceutical composition of claim 74 , wherein the ethanol is 95% (v/v) ethanol.
79 . A gel pharmaceutical composition consisting essentially of:
a) about 0.1% to about 10.0% (w/w) testosterone; b) about 30.0% to about 98.0% (w/w) ethanol; c) about 0.1% to about 5.0% (w/w) isopropyl myristate; d) about 0.1% to about 5.0% (w/w) of an anionic polymer neutralized with an amount of sodium hydroxide; and e) water.
80 . The pharmaceutical composition of claim 79 , wherein the anionic polymer is a polyacrylic acid.
81 . The gel pharmaceutical composition of claim 80 , wherein the polyacrylic acid is a carbopol.
82 . The gel pharmaceutical composition of claim 79 , wherein the sodium hydroxide is 0.1 N NaOH and the anionic polymer is a carbopol.
83 . The gel pharmaceutical composition of claim 79 , wherein the ethanol is 95% (v/v) ethanol.
84 . A gel pharmaceutical composition that is obtained by combining the following:
a) about 0.1% to about 10.0% (w/w) testosterone; b) about 30.0% to about 98.0% (w/w) ethanol; c) about 0.1% to about 5.0% (w/w) isopropyl myristate; d) about 0.1% to about 5.0% (w/w) of a thickener that is an anionic polymer; e) an amount of sodium hydroxide sufficient to form a gel; and f) water.
85 . The gel pharmaceutical composition of claim 84 , wherein the sodium hydroxide is 0.1 N NaOH.
86 . The pharmaceutical composition of claim 84 , wherein the anionic polymer is a polyacrylic acid.
87 . The gel pharmaceutical composition of claim 86 , wherein the polyacrylic acid is a carbopol.
88 . The gel pharmaceutical composition of claim 84 , wherein the sodium hydroxide is 0.1 N NaOH and the anionic polymer is a carbopol.
89 . The gel pharmaceutical composition of claim 84 , wherein the ethanol is 95% v/v ethanol.
90 . A method of treating hypogonadism in a human male comprising applying a therapeutically effective dose of a gel pharmaceutical composition to an area of skin of the human male, the composition comprising:
a) about 0.1% to about 10.0% (w/w) testosterone; b) about 30.0% to about 98.0% (w/w) ethanol; c) about 0.1% to about 5.0% (w/w) isopropyl myristate; d about 0.1% to about 5.0% (w/w) of an anionic polymer neutralized with an amount of sodium hydroxide; and e) water.
91 . The method of claim 90 , wherein the anionic polymer is a polyacrylic acid.
92 . The method of claim 91 , wherein the polyacrylic acid is a carbopol.
93 . The method of claim 90 , wherein the sodium hydroxide is 0.1 N NaOH and the anionic polymer is a carbopol.
94 . The method of claim 90 , wherein the ethanol is 95% (v/v) ethanol.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.